3805 OLD EASTON ROAD, DOYLESTOWN, PA
Stockholder Vote Results; Three Directors Elected at Annual Meeting
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Annual Report to Security Holders
Announces Closing of Oversubscribed $30 Million Private Placement
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD, Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence